R3 biotech, backed by Silicon Valley investors and ARPA-H ties, pitched 'body replacement cloning' of brain-damaged human clones for spare organs.
MIT Technology Review uncovered documents showing R3, a longevity startup founded by John Schloendorn and Alice Gilman, developed a technical road map for 'body replacement cloning' — creating humans or primates without complete brains to serve as organ sources. The company presented this concept at a $70,000-per-ticket event organized by Peter Diamandis in September 2024. R3 has raised investor funding, has ARPA-H connections, and planned primate experiments in the Caribbean. The company denies intent to clone humans but has not denied internal discussions of the concept.
No immediate API or tooling implications here. However, if you're building AI tools for longevity research, genomics pipelines, or biotech data infrastructure, this story signals incoming regulatory scrutiny that will tighten data governance requirements for any platform touching human cloning or synthetic biology adjacent research.
If you're building software for biotech or genomics clients, audit your terms of service this week to confirm your platform explicitly prohibits use cases involving human cloning research — before regulators make this a compliance checkbox.
Go to claude.ai and open a new conversation
Tags
Signals by role
Also today
Tools mentioned